Lorna A. Knick

About

Lorna A. Knick represents public and private companies in mergers and acquisitions at Wyrick Robbins Yates & Ponton. She advises public companies on corporate governance, securities laws, and stock exchange requirements. Her transaction experience also includes equity offerings, convertible debt offerings, and restructurings. She earned her J.D., cum laude, from Duke Law School, where she held a Stafford Law Scholarship. Best Lawyers recognized her in “Ones to Watch” for Securities/Capital Markets Law (2025-2026). She also advises financial institutions on capital markets matters.

Who is a good fit for Lorna A. Knick

• Public companies pursuing acquisitions with corporate governance and securities law considerations.
• Private companies seeking legal representation in a merger.

Education and admissions

Education

• University of North Carolina at Chapel Hill, B.A. in Political Science
• Duke Law School, J.D.

Bar admissions

North Carolina

Recognition

• Listed among North Carolina Super Lawyers: Securities & Corporate Finance - Rising Star (2022-2025)
• Listed among Best Lawyers “Ones to Watch”: Securities/Capital Markets Law (2025-2026)

Specialties

Representative matters

As described on the firm’s website.

• Represented a Nasdaq-listed clinical stage pharmaceutical company in a registered direct and concurrent private placement totaling approximately $18 million. ($18,000,000)
• Represented a Nasdaq-listed cloud software company in underwritten secondary offerings totaling approximately $400 million. ($400,000,000)
• Represented a Nasdaq-listed clinical-stage pharmaceutical company in multiple equity offerings totaling approximately $95 million and a convertible debt facility for up to $70 million.
• Advised a Nasdaq-listed clinical-stage pharmaceutical company in a tri-party merger with two privately held pharmaceutical companies in an all-stock transaction.
• Represented a Nasdaq-listed pharmaceutical development company in multiple equity offerings totaling approximately $120 million. ($120,000,000)
• Advised a Nasdaq-listed biopharmaceutical company in an agreement to acquire by merger another public biopharmaceutical company in an all-stock transaction valued at approximately $15.6 million. ($15,600,000)
• Advised the lead underwriter in an approximately $31 million initial public offering for a bank holding company. ($31,000,000)
• Advised the sole underwriter in an approximately $19.5 million Regulation A+ offering and concurrent Nasdaq uplisting of an electric vehicle company. ($19,500,000)
• Attends Board and committee meetings of a local specialty pharmaceutical company listed on Nasdaq and represents that company in its capital raising transactions;

Deal profile

Typical deal size

Any deal size

Remote work

In-person / regional